Key result
A reduced systemic heparin dose with a closed, phosphorylcholine-coated circuit was associated with a lower requirement for allogeneic blood products (OR 0.55; 95% CI 0.34-0.92; p=0.02).
Why the study?
Does a closed, phosphorylcholine coated circuit with reduced systemic heparin dose improve hospital outcomes and reduce bleeding in low to moderate risk patients undergoing elective isolated coronary operations?
Cohort (n=364)
Does a closed, phosphorylcholine coated circuit with reduced systemic heparin dose improve hospital outcomes and reduce bleeding in low to moderate risk patients undergoing elective isolated coronary operations?
Odds Ratio: 0.55 (95% CI 0.34–0.92)
p-value: p=0.02
A reduced systemic anticoagulation protocol using a closed, phosphorylcholine coated circuit is feasible and significantly reduces blood loss, transfusion requirements, and severe morbidity in patients undergoing elective coronary operations.
No takes yet. Share an insight, caveat, or question.
Caution against immediate adoption; extends observational data but leaves open randomized confirmation in coronary surgery.
Ranucci et al. (2004) conducted a cohort in coronary revascularization with cardiopulmonary bypass (n=364). closed, phosphorylcholine coated circuits and reduced systemic heparin dose vs. conventional open circuits and full systemic anticoagulation was evaluated on requirement for allogeneic blood products (OR 0.55, 95% CI 0.34-0.92, p=0.02). A reduced systemic heparin dose with a closed, phosphorylcholine-coated circuit was associated with a lower requirement for allogeneic blood products (OR 0.55; 95% CI 0.34-0.92; p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: